Greenwich LifeSciences In...

NASDAQ: GLSI · Real-Time Price · USD
9.95
-0.03 (-0.30%)
At close: May 02, 2025, 3:59 PM
9.99
0.45%
After-hours: May 02, 2025, 04:02 PM EDT

Company Description

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.

Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.

Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc. logo
Country United States
IPO Date Sep 25, 2020
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Snehal S. Patel

Contact Details

Address:
Building 14
Stafford, Texas
United States
Website https://greenwichlifesciences.com

Stock Details

Ticker Symbol GLSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001799788
CUSIP Number 396879108
ISIN Number US3968791083
Employer ID 20-5473709
SIC Code 2834

Key Executives

Name Position
Snehal S. Patel Chief Executive Officer, Chief Financial Officer & Director
Dr. Christine T. Fischette Ph.D. Vice President of Business Development
Dr. Frank Joseph Daugherty M.D. Chief Medical Officer & Director
Dr. Jaye L. Thompson Ph.D. Vice President Clinical & Regulatory Affairs
Eric Rothe Founder & Independent Director

Latest SEC Filings

Date Type Title
Apr 29, 2025 4 Filing
Apr 22, 2025 4 Filing
Apr 15, 2025 10-K Annual Report
Apr 08, 2025 4 Filing
Apr 07, 2025 4 Filing
Mar 31, 2025 NT 10-K Filing
Jan 13, 2025 4 Filing
Jan 08, 2025 4 Filing
Jan 07, 2025 4 Filing
Jan 06, 2025 4 Filing